均瑤健康(605388.SH):擬終止籌劃獲取上海鴻鎰遠供應鏈51%股權事項
格隆匯7月20日丨均瑤健康(605388.SH)公佈,公司自籌劃此次重大資產重組事項(公司擬自行或指定其關聯方以現金支付方式,通過受讓王學毅持有的上海鴻鎰遠供應鏈管理有限公司51%股權,形成對標的公司的控制權。)以來,嚴格按照相關法律法規要求,全力推進此次重大資產重組事項,與此次重大資產重組有關各方進行了積極磋商、反覆探討和溝通,並及時根據籌劃進展按照規定履行信息披露義務。截至公吿日,鑑於交易各方對交易條款進行多輪協商和談判後,交易各方最終未能就交易對價和合作範圍等核心條款達成一致,從而未能達成進入下一步實質階段的前提條件,經審慎研究,公司決定終止籌劃此次重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.